약물감시 시장 : 유형별, 제품수명주기별, 제공 방법별, 프로세스 플로우별, 치료 분야별, 최종사용자별 - 세계 예측(2025-2032년)

The Pharmacovigilance Market is projected to grow by USD 34.17 billion at a CAGR of 16.25% by 2032.

A succinct orientation to contemporary pharmacovigilance imperatives reflecting data complexities, regulatory evolution, and organizational readiness for safety governance

Pharmacovigilance sits at the intersection of patient safety, regulatory stewardship, and commercial sustainability. As therapeutic innovation accelerates and real-world evidence gains prominence, safety monitoring paradigms must adapt to more complex data sources, accelerated development timelines, and heightened regulatory scrutiny. This introduction synthesizes the core drivers that are reshaping the discipline, from data architecture and automation to workforce models and cross-functional governance.

Contemporary safety functions are increasingly required to balance rapid signal detection with methodical risk evaluation, while enabling product teams to make timely, evidence-informed decisions. The integration of electronic health records, registries, and patient-reported outcomes is expanding both the volume and heterogeneity of safety inputs, necessitating robust data curation and validation practices. Meanwhile, regulators are signaling expectations for stronger post-market surveillance and risk minimization planning, prompting organizations to re-evaluate roles, workflows, and technology investments.

Transitioning from manual, document-centric approaches to modular, analytics-driven systems is no longer optional for organizations aiming to maintain compliance and competitive differentiation. This introduction establishes the foundational context for the subsequent sections, emphasizing that pragmatic governance, scalable data strategy, and skilled multidisciplinary teams are essential to ensure safety objectives are met across product lifecycles and global markets.

An exploration of the major structural and technological shifts redefining pharmacovigilance operations including AI, real-world evidence, and modern regulatory expectations

The pharmacovigilance landscape is experiencing transformative shifts driven by technological innovation, regulatory modernization, and strategic sourcing. Artificial intelligence and machine learning are enabling earlier identification of safety signals through pattern recognition across disparate datasets, while natural language processing improves the extraction of relevant information from free-text sources such as medical notes and social media. These capabilities are complemented by maturing real-world data ecosystems that allow safety teams to augment traditional clinical trial evidence with longitudinal patient information.

Concurrently, regulators are evolving expectations for transparency, proactive risk management, and the incorporation of real-world evidence into safety decision-making. This regulatory momentum is prompting organizations to move beyond compliance checklists and toward continuous evidence generation frameworks that emphasize lifecycle safety. Operationally, many safety organizations are adopting hybrid delivery models that combine in-house expertise for strategic oversight with outsourced capabilities for scale and specialized analytics, enabling rapid ramp-up during peak activities.

Culturally, cross-functional integration of pharmacovigilance with clinical development, regulatory affairs, and commercial teams is becoming essential to accelerate time-to-decision and to design pragmatic risk mitigation strategies. As a result, leaders are investing in change management, upskilling, and formalized governance to ensure that new tools and data sources are leveraged responsibly and effectively. Together, these shifts redefine what it means to deliver high-quality patient safety in an increasingly dynamic therapeutic and regulatory environment.

A comprehensive assessment of how 2025 tariff measures have reshaped supply chain choices, outsourcing strategies, and cost governance across pharmacovigilance operations

The introduction of enhanced tariffs in 2025 has produced a cascade of operational and strategic responses across the pharmacovigilance ecosystem, affecting supply chains, service procurement, and cost structures. Increased duties on imported goods have elevated the cost base for certain medical devices and supporting hardware, prompting some organizations to re-evaluate capital procurement timing and to consider localized sourcing to reduce exposure to cross-border levies. These procurement pressures have indirect implications for pharmacovigilance, especially where instrument-driven diagnostics or third-party safety hardware are part of surveillance workflows.

In addition, tariff-driven cost inflation has influenced outsourcing decisions. Some sponsors have shifted to more geographically balanced outsourcing arrangements, favoring service providers with delivery centers in regions with lower tariff exposure or with established nearshore capabilities. This redistribution aims to preserve budget flexibility for data analytics investments while maintaining capacity for case processing, medical review, and query management. At the same time, vendor contracts are being renegotiated to include clauses that address tariff volatility, cost pass-through, and contingency staffing to preserve continuity of safety operations.

Regulatory compliance budgets have also felt downstream effects. Organizations are prioritizing investments that directly enhance signal detection and regulatory responsiveness, given the operational constraints imposed by tariff-related cost pressures. Overall, the cumulative impact of the 2025 tariff changes has accelerated strategic localization of supply and delivery, strengthened contractual risk management, and intensified the focus on efficiency improvements across pharmacovigilance processes to preserve program resilience and patient safety outcomes.

In-depth segmentation analysis revealing how safety methodology, lifecycle stage, delivery models, process architecture, therapeutic focus, and end-user profiles shape pharmacovigilance priorities

Key segmentation insights reveal differentiated strategic priorities across methods of safety capture, clinical development stages, delivery models, process architecture, therapeutic focus, and end-user types. When considering Type, approaches such as Cohort Event Monitoring, EHR Mining, Intensified ADR Reporting, Spontaneous Reporting, and Targeted Spontaneous Reporting each impose distinct data quality, latency, and validation requirements; Cohort Event Monitoring and EHR Mining demand strong longitudinal data linkage and advanced analytics, while Spontaneous Reporting emphasizes rapid intake and standardized coding workflows.

Considering Product Life Cycle, requirements vary significantly across Phase I, Phase II, Phase III, Phase IV, and Pre-clinical stages. Early phases prioritize safety signal characterization and close medical oversight, whereas Phase IV activities emphasize long-term risk minimization and integration of post-market surveillance data. Delivery Mode also dictates capability design: In-house models support strategic oversight, knowledge retention, and direct regulatory interface, while Outsourced models provide scalability, specialized expertise, and cost flexibility during peak activity windows.

Process Flow segmentation highlights distinct operational foci across Case Data Management, Risk Management System, and Signal Detection. Case Data Management encompasses case data analysis, case logging, and medical reviewing and reporting, requiring robust case-tracking, quality control, and therapeutic expertise. The Risk Management System incorporates risk evaluation system and risk mitigation system capabilities that support lifecycle risk assessment and the implementation of targeted interventions. Signal Detection functions involve adverse event analysis, adverse event logging, and adverse event review and reporting, relying on statistical monitoring, data harmonization, and multidisciplinary adjudication.

Therapeutic Area segmentation-spanning cardiovascular, infectious diseases, neurology, oncology, and respiratory-shapes the expected event typologies, monitoring cadence, and specialist expertise required for accurate causality assessment. End-user distinctions among biotechnology companies, medical device manufacturers, and pharmaceuticals influence contracting models, acceptable risk-tolerance thresholds, and the degree of regulatory engagement expected, with each end-user type balancing speed to insight against the need for rigorous medical and regulatory evidence.

A regional appraisal of how jurisdictional variation in regulation, data infrastructure, and service capabilities demands integrated global standards with localized execution strategies

Regional dynamics materially influence operational design, regulatory strategy, and resourcing decisions across jurisdictions. In the Americas, legacy regulatory frameworks are being augmented by accelerated adoption of real-world evidence and robust post-market surveillance expectations, driving demand for scalable analytics platforms and strong local pharmacovigilance expertise. This region favors integrated end-to-end solutions that can respond to both centralized regulatory inquiries and decentralized healthcare data sources.

Across Europe, Middle East & Africa, heterogeneity in regulatory maturities requires adaptable engagement strategies. The European regulatory environment places emphasis on transparency, data protection, and cross-border pharmacovigilance cooperation, while markets in the Middle East and Africa present variable infrastructure and data availability that often necessitate hybrid approaches combining centralized analytics with targeted local studies. Consequently, organizations operating in this broad region must balance pan-regional standardization with localized execution flexibility.

The Asia-Pacific landscape is characterized by rapid adoption of digital health technologies, growing clinical trial activity, and an expanding pool of specialized service providers. Diverse regulatory regimes in the region create opportunities for nearshore delivery models and regional hubs that provide cost efficiency and time zone alignment for sponsors. Together, these regional insights suggest that successful pharmacovigilance strategies require a mosaic approach: harmonized global standards layered with regionally tailored processes and partnerships that reflect local regulatory expectations, data ecosystems, and operational readiness.

An evaluative perspective on competitive positioning where technological depth, therapeutic expertise, and flexible delivery models determine long-term vendor relevance

Companies operating in the pharmacovigilance space are competing on the basis of technological capability, domain expertise, and the ability to deliver flexible delivery models that meet client-specific regulatory and operational needs. Market-leading organizations are investing in modular analytics platforms that support both automated signal detection and configurable workflow orchestration, enabling rapid adaptation to sponsor preferences and inspection requirements. These investments are frequently paired with focused recruitment or partnership strategies to secure therapeutic-area specialists and experienced safety physicians capable of nuanced causality assessment.

Strategic partnerships between technology providers, contract safety organizations, and data custodians are increasingly common, enabling bundled offerings that combine data access, analytics, and case processing at scale. At the same time, nimble boutique providers differentiate through deep therapeutic expertise or specialized services such as intensified ADR reporting programs, targeted spontaneous reporting frameworks, and bespoke risk evaluation systems. Buyers are scrutinizing vendor governance structures, evidence of regulatory inspection readiness, and demonstrable outcomes such as cycle-time reductions and improvements in signal-to-noise ratios.

Competitive positioning is also influenced by geographic delivery footprint and the ability to provide hybrid in-house and outsourced models that align with client risk tolerances. Companies that can demonstrate robust quality systems, transparent pricing models, and agile implementation methodologies are most likely to secure long-term partnerships as sponsors prioritize reliability, scalability, and the capacity to integrate emerging data streams into established pharmacovigilance processes.

Actionable strategic initiatives for leaders to embed advanced analytics, hybrid sourcing, governance, and workforce development into robust pharmacovigilance programs

Industry leaders should prioritize a focused set of strategic initiatives to strengthen safety outcomes while maintaining operational resilience. First, accelerate integration of advanced analytics and natural language processing into core surveillance activities to reduce manual effort, increase signal sensitivity, and shorten time-to-insight. Simultaneously, establish clear validation and governance frameworks to ensure algorithmic outputs meet regulatory and clinical standards.

Second, adopt a hybrid sourcing strategy that combines in-house leadership for critical judgment functions with outsourced scale for routine processing and specialized analytics. This approach preserves institutional knowledge while enabling rapid capacity management during clinical accelerations or post-market demands. Third, cultivate cross-functional governance that embeds pharmacovigilance metrics into development decision-making, regulatory planning, and commercial strategy to ensure safety considerations are factored into lifecycle choices.

Fourth, invest in workforce development to upskill safety professionals in data science, regulatory intelligence, and evidence synthesis, thereby enhancing the team's ability to interpret complex signals and to communicate decisions to stakeholders. Fifth, design contractual safeguards with vendors to manage geopolitical and tariff-related risks, including clauses for cost adjustment, contingency staffing, and data sovereignty. By implementing these focused actions, organizations can enhance their ability to detect and mitigate risks, preserve compliance, and sustain trust among providers, payers, and patients.

A rigorous multi-method research approach combining secondary review, expert interviews, triangulation, and scenario analysis to ensure evidence-based and pragmatic insights

The research methodology underpinning this analysis combined a layered approach to evidence gathering, validation, and synthesis to ensure rigor and practical relevance. The process began with comprehensive secondary research encompassing regulatory guidance, peer-reviewed literature, and public domain safety communications to map current standards, recent policy shifts, and methodological innovations. This foundation informed targeted primary research involving structured interviews with safety leaders, regulatory specialists, clinical development executives, and vendors to capture operational realities and evolving priorities.

Data triangulation techniques were applied to reconcile divergent perspectives, with scenario-based analyses used to stress-test strategic responses against variables such as tariff shifts, regional regulatory changes, and rapid adoption of new data sources. Quality control included methodological audits, cross-validation of key assertions with independent domain experts, and iterative review cycles to ensure factual accuracy and practical applicability. Wherever analytic models were used to illustrate process implications, they were accompanied by sensitivity examinations to highlight key assumptions and to delineate areas requiring further empirical validation.

This multi-method approach was designed to deliver findings that are both evidence-based and pragmatically oriented, supporting leaders in translating strategic insight into operational decisions while accounting for the inherent complexity of global pharmacovigilance ecosystems.

A concluding synthesis emphasizing the necessity of integrated data strategies, adaptive governance, and resilient sourcing to secure sustained pharmacovigilance excellence

In conclusion, pharmacovigilance is undergoing substantive transformation driven by advances in analytics, shifts in regulatory expectations, and evolving commercial and geopolitical pressures. Organizations that embrace data integration, governance modernization, and hybrid delivery models will be better positioned to detect safety signals earlier, to respond more decisively, and to maintain regulatory and public trust. The cumulative effects of supply chain and tariff dynamics underscore the importance of contractual resilience and geographic diversification in sustaining program continuity.

The segmentation and regional analyses highlight that there is no single operational model that fits all contexts; instead, successful programs align methodological choices with lifecycle stage, therapeutic complexity, and end-user priorities. Competitive advantage will accrue to organizations that combine technological investments with domain expertise and agile operating models. Ultimately, pharmacovigilance must be treated as a strategic capability that protects patients while enabling therapeutic innovation, and the pathway to that capability requires deliberate investments in people, process, and technology.

Leaders should view the recommendations and insights in this report as a practical blueprint for action: prioritize analytics and governance, refine sourcing strategies, and invest in the workforce to sustain high-quality safety outcomes in a rapidly changing environment.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Integration of artificial intelligence and machine learning for proactive adverse event signal detection and risk assessment
• 5.2. Adoption of real-world evidence derived from electronic health records and wearable tech to complement safety data
• 5.3. Expansion of patient-centric pharmacovigilance apps enabling direct reporting of adverse events via mobile platforms
• 5.4. Implementation of blockchain technologies to ensure auditability and integrity of individual case safety reports across systems
• 5.5. Deployment of natural language processing tools to mine social media and clinical notes for early adverse event signals
• 5.6. Shift towards global regulatory harmonization and data standardization under ICH E2B(R3) guidelines for cross-border safety reporting
• 5.7. Emergence of cloud-based safety databases with automated workflows for case intake, triage, and regulatory submission
• 5.8. Growth in decentralized clinical trials requiring remote pharmacovigilance monitoring and virtual patient safety assessments

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Pharmacovigilance Market, by Type

• 8.1. Cohort Event Monitoring
• 8.2. EHR Mining
• 8.3. Intensified ADR Reporting
• 8.4. Spontaneous Reporting
• 8.5. Targeted Spontaneous Reporting

9. Pharmacovigilance Market, by Product Life Cycle

• 9.1. Phase I
• 9.2. Phase II
• 9.3. Phase III
• 9.4. Phase IV
• 9.5. Pre-clinical

10. Pharmacovigilance Market, by Delivery Mode

• 10.1. In-house
• 10.2. Outsourced

11. Pharmacovigilance Market, by Process Flow

• 11.1. Case Data Management
  • 11.1.1. Case Data Analysis
  • 11.1.2. Case Logging
  • 11.1.3. Medical Reviewing & Reporting
• 11.2. Risk Management System
  • 11.2.1. Risk Evaluation System
  • 11.2.2. Risk Mitigation System
• 11.3. Signal Detection
  • 11.3.1. Adverse Event Analysis
  • 11.3.2. Adverse Event Logging
  • 11.3.3. Adverse Event Review & Reporting

12. Pharmacovigilance Market, by Therapeutic Area

• 12.1. Cardiovascular
• 12.2. Infectious Diseases
• 12.3. Neurology
• 12.4. Oncology
• 12.5. Respiratory

13. Pharmacovigilance Market, by End-user

• 13.1. Biotechnology Companies
• 13.2. Medical Device Manufacturers
• 13.3. Pharmaceuticals

14. Pharmacovigilance Market, by Region

• 14.1. Americas
  • 14.1.1. North America
  • 14.1.2. Latin America
• 14.2. Europe, Middle East & Africa
  • 14.2.1. Europe
  • 14.2.2. Middle East
  • 14.2.3. Africa
• 14.3. Asia-Pacific

15. Pharmacovigilance Market, by Group

• 15.1. ASEAN
• 15.2. GCC
• 15.3. European Union
• 15.4. BRICS
• 15.5. G7
• 15.6. NATO

16. Pharmacovigilance Market, by Country

• 16.1. United States
• 16.2. Canada
• 16.3. Mexico
• 16.4. Brazil
• 16.5. United Kingdom
• 16.6. Germany
• 16.7. France
• 16.8. Russia
• 16.9. Italy
• 16.10. Spain
• 16.11. China
• 16.12. India
• 16.13. Japan
• 16.14. Australia
• 16.15. South Korea

17. Competitive Landscape

• 17.1. Market Share Analysis, 2024
• 17.2. FPNV Positioning Matrix, 2024
• 17.3. Competitive Analysis
  • 17.3.1. Accenture, PLC
  • 17.3.2. Bristol-Myers Squibb Company
  • 17.3.3. Capgemini SE
  • 17.3.4. ClinChoice
  • 17.3.5. F. Hoffmann-La Roche AG
  • 17.3.6. GlaxoSmithKline PLC
  • 17.3.7. HCL Technologies Limited
  • 17.3.8. ICON PLC
  • 17.3.9. Infosys Limited
  • 17.3.10. International Business Machines Corporation
  • 17.3.11. IQVIA Inc.
  • 17.3.12. ITclinical
  • 17.3.13. Laboratory Corporation of America Holdings
  • 17.3.14. Linical Co., Ltd.
  • 17.3.15. Novartis AG
  • 17.3.16. Oracle Corporation
  • 17.3.17. Parexel International
  • 17.3.18. Pfizer Inc.
  • 17.3.19. Quanticate International limited
  • 17.3.20. Sanofi S.A.
  • 17.3.21. Syneos Health
  • 17.3.22. TAKE Solutions Limited
  • 17.3.23. TATA Consultancy Services Limited
  • 17.3.24. Wipro Limited